Importance of continued testicular suppression in hormone-refractory prostate cancer.

Publisher Website
Google Scholar
Abstract
PURPOSEPatients in whom prostate cancer progresses despite testicular androgen ablation are generally said to have cancers that have become resistant to hormonal maneuvers. If androgen suppression has been pharmacologic, this therapy is often stopped before consideration of other systemic treatments. This exploratory study sought clinical correlates of experimental evidence that there may be substantial acceleration of tumor growth after cessation of androgen suppression.MATERIALS AND METHODSA retrospective multivariate analysis was performed on survival data for 341 patients treated on four clinical trials of secondary therapy for hormone-refractory prostate cancer. Factors included in the model were recent weight loss, age, performance status, disease site (soft tissue v bone-dominant), prior radiotherapy, and continued androgen suppression v discontinued exogenous endocrine therapy.RESULTSRecent weight loss, age, performance status, and disease site were important prognostic factors for survival durati...

This publication has 0 references indexed in Scilit: